NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia

Journal of Clinical Oncology

Volumn 28, Issue 6, 2010, Pages 955-959

  Rubnitz, Jeffrey E ^a   Inaba, Hiroto ^a   Ribeiro, Raul C ^a   Pounds, Stanley ^a   Rooney, Barbara ^a   Bell, Teresa ^a   Pui, Ching Hon ^a   Leung, Wing ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CELL TRANSPLANTATION; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; ENGRAFTMENT; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HAPLOIDENTICAL NATURAL KILLER CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; PATIENT SAFETY; PHENOTYPE; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; CANCER STAGING; HAPLOTYPE; IMMUNOTHERAPY; NATURAL KILLER CELL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEASIBILITY STUDIES; FEMALE; HAPLOTYPES; HUMANS; IMMUNOTHERAPY; INFANT; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 77949898005     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.4590     Document Type: Article

References (20)

1. Creutzig U, Zimmermann M, Lehrnbecher T, et al: Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 98. J Clin Oncol 24:4499-4506, 2006 (Pubitemid 46646248)
2. Lange BJ, Smith FO, Feusner J, et al: Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 111:1044-1053, 2008 (Pubitemid 351213382)
3. Becton D, Dahl GV, Ravindranath Y, et al: Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 107:1315-1324, 2006 (Pubitemid 43242364)
4. Stevens RF, Hann IM, Wheatley K, et al: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 101:130-140, 1998 (Pubitemid 28197786)
5. Gibson BE, Wheatley K, Hann IM, et al: Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19:2130-2138, 2005 (Pubitemid 41741605)
6. Lie SO, Abrahamsson J, Clausen N, et al: Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: Results of NOPHO-AML trials. Br J Haematol 122:217-225, 2003 (Pubitemid 36859606)
7. Horan JT, Alonzo TA, Lyman GH, et al: Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: The Children's Oncology Group. J Clin Oncol 26:5797-5801, 2008
8. Caligiuri MA: Human natural killer cells. Blood 112:461-469, 2008
9. Leung W, Iyengar R, Turner V, et al: Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172:644-650, 2004 (Pubitemid 38020523)
10. Leung W, Iyengar R, Triplett B, et al: Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174:6540-6545, 2005 (Pubitemid 40663849)
11. Hsu KC, Keever-Taylor CA, Wilton A, et al: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105:4878-4884, 2005 (Pubitemid 40807317)
12. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057, 2005
13. Iyengar R, Handgretinger R, Babarin-Dorner A, et al: Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 5:479-484, 2003 (Pubitemid 38028707)
14. Kurt B, Flynn P, Shenep JL, et al: Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 113:376-382, 2008
15. Leung WH, Turner V, Richardson SL, et al: Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 62:399-407, 2001 (Pubitemid 32298983)
16. Leung W, Iyengar R, Leimig T, et al: Phenotype and function of human natural killer cells puri- fied by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 54:389-394, 2005 (Pubitemid 40238933)
17. Schichman SA, Suess P, Vertino AM, et al: Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant 29:243-248, 2002 (Pubitemid 34189517)
18. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al: Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 123:243-252, 2003 (Pubitemid 37305058)
19. Müller S, Schulz A, Reiss U, et al: Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Bone Marrow Transplant 24:575-581, 1999 (Pubitemid 29446130)
20. Copelan EA: Hematopoietic stem-cell transplantation. N Engl J Med 354:1813-1826, 2006